Augmentin Articles
Augmentin Injunction In UK
29 April 1996
Twice-daily Augmentin
18 March 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
Twice-Daily Augmentin Approved
19 February 1996
Effects of Genomics On Antibacterial R&D
20 November 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
SmithKline Beecham: new Augmentin data
9 October 1995
Warner-Lambert's cefdinir: new findings
2 October 1995
Interest Expenses, Currency Hit SB's Results
31 July 1995
"Strong Underlying Growth" At SB In 1st Qtr
24 April 1995
Dutch Govt Has Mistaken Impression Of Drug Prices
13 March 1995
South African Pharma Market $4 Billion In 2002
21 November 1994
Pfizer: Record Number Of Drugs In Phases II & III
31 October 1994
Analysts Upgrade SmithKline Beecham
31 October 1994
SmithKline Beecham On Adapting To Change
10 October 1994
DDT's New Global Pharma Market Review 1994
10 October 1994
French Reforms Hit Antibiotic Sales
3 October 1994
SB Lifts 2nd Qtr Earnings 20%
25 July 1994
EUROPE STOCK COMMENT
13 June 1994
GENERIC THREAT TO AUGMENTIN IN UK
6 June 1994
EUROPEAN STOCK COMMENT
30 May 1994
SMITHKLINE BEECHAM'S MIXED 1st QTR
2 May 1994
ISRAELI PHARMA MARKET STAGNANT IN 1993
18 April 1994
SALES SURGE FOR SOME DRUGS IN ITALY
14 March 1994
SMITHKLINE BEECHAM PLEASED WITH RESULTS
28 February 1994
LIKELY IMPACT ON DRUG FIRMS OF ITALIAN REFORMS
17 January 1994
DRUGMAKERS IN ITALY PANIC ON NEW SALES FEARS
10 January 1994
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
BIAXIN EFFECTIVE FOR OTITIS MEDIA
25 October 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
SB BEECHAM RESULTS; EXPLOITS STRENGTHS
1 March 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
RESISTANCE ENSURES AUGMENTIN'S FUTURE
15 June 1992
AUGMENTIN AS EFFECTIVE AS COMBO REGIMENS
4 May 1992
MOMENTUM OF 1991 CONTINUES AT SB
27 April 1992
DECEMBER US APPROS REVIEWED
20 January 1992
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
